Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label Galectin-1. Show all posts
Showing posts with label Galectin-1. Show all posts

Monday, August 10, 2015

Astrocyte reactivity after brain injury—: The role of galectins 1 and 3

So should we get galectin 3 delivered to the brain after a stroke to repair astrocytes? Whom do we contact to answer this very simple question? Or will 50 years pass again because we have no one following and executing a stroke strategy?
http://onlinelibrary.wiley.com/doi/10.1002/glia.22898/full

  1. Swetlana Sirko1,2,
  2. Martin Irmler3,
  3. Sergio Gascón1,2,
  4. Sarah Bek1,
  5. Sarah Schneider1,2,
  6. Leda Dimou1,2,
  7. Jara Obermann4,
  8. Daisylea De Souza Paiva1,5,
  9. Francoise Poirier6,
  10. Johannes Beckers3,7,
  11. Stefanie M. Hauck4,
  12. Yves-Alain Barde8 and
  13. Magdalena Götz1,2,9,*
Article first published online: 6 AUG 2015
DOI: 10.1002/glia.22898

SEARCH

Keywords:

  • glia proliferation;
  • neurosphere;
  • genomewide analysis

Abstract

Astrocytes react to brain injury in a heterogeneous manner with only a subset resuming proliferation and acquiring stem cell properties in vitro. In order to identify novel regulators of this subset, we performed genomewide expression analysis of reactive astrocytes isolated 5 days after stab wound injury from the gray matter of adult mouse cerebral cortex. The expression pattern was compared with astrocytes from intact cortex and adult neural stem cells (NSCs) isolated from the subependymal zone (SEZ). These comparisons revealed a set of genes expressed at higher levels in both endogenous NSCs and reactive astrocytes, including two lectins—Galectins 1 and 3. These results and the pattern of Galectin expression in the lesioned brain led us to examine the functional significance of these lectins in brains of mice lacking Galectins 1 and 3. Following stab wound injury, astrocyte reactivity including glial fibrillary acidic protein expression, proliferation and neurosphere-forming capacity were found significantly reduced in mutant animals. This phenotype could be recapitulated in vitro and was fully rescued by addition of Galectin 3, but not of Galectin 1. Thus, Galectins 1 and 3 play key roles in regulating the proliferative and NSC potential of a subset of reactive astrocytes. GLIA 2015.

Introduction

Reactive gliosis is a widespread reaction of glial cells to pathological processes in the brain. It involves astrocytes, NG2 glia, and microglia that mediate beneficial and adverse effects, such as wound closure and scar formation, respectively (Kettenmann et al., 2011). Recent work indicates a striking heterogeneity in the reaction of each type of glial cells (Anderson et al., 2014; Burda and Sofroniew, 2014; Dimou and Götz, 2014). This could be best demonstrated by live in vivo imaging, which revealed a surprisingly heterogeneous reaction of astrocytes reacting to stab wound injury in the adult murine cerebral cortex gray matter (GM), with some astrocytes hardly reacting at all, others polarizing toward the injury site and yet others proliferating and generating two daughter astrocytes (Bardehle et al., 2013). Furthermore, clonal analysis demonstrated that the differential reaction of astrocyte subtypes is seemingly related to their distinct developmental origin (Martín-López et al., 2013). In view of this heterogeneity, it is now important to address the mechanisms regulating the reaction of these distinct astrocyte subsets after brain injury.
Astrocytes resuming cell division after lesion are of particular importance, as proliferation is the only means to increase astrocyte numbers at the injury site in the cerebral cortex GM (Bardehle et al., 2013). Indeed, proliferating astrocytes are critical for restricting the injury size and the number of infiltrating cells and inflammation, since their elimination has been shown to aggravate brain damage after lesion (Burda and Sofroniew, 2014). Interestingly, astrocyte proliferation in the GM is highly injury-dependent and does not occur upon amyloid plaque deposition or even pronounced neuronal cell death, in spite of profound microglia activation and proliferation (Behrendt et al., 2013; Sirko et al., 2013). Instead, it is selectively elicited upon injury involving alterations of the blood brain barrier, such as traumatic, ischemic, and demyelinating injuries (Behrendt et al., 2013; Dimou and Götz, 2014; Gadea et al., 2008; Götz and Sirko, 2013; Kamphuis et al., 2012). These injury-specific differences led to the identification of signals regulating reactive astrocyte proliferation, including endothelin-1, sonic hedgehog and fibroblast growth factor (FGF) signaling (Gadea et al., 2008; Kang et al., 2014; Sirko et al., 2013; Zamanian et al., 2012). To obtain a more comprehensive view on the key regulators of reactive astrocyte proliferation, we set out to examine the pattern of gene expression in reactive astrocytes at the peak of their proliferation following stab wound injury in comparison to nonproliferative astrocytes in the intact adult cerebral cortex GM.
As a subset of proliferating reactive astrocytes acquire neural stem cell (NSC) potential after injury, monitored by the ability to form multipotent, self-renewing neurospheres (Buffo et al., 2008; Grande et al, 2013; Sirko et al., 2013), this prompts the question how much of the gene expression changes of reactive astrocytes may be shared with NSCs. Only genomewide expression analysis comparing reactive astrocytes, NSCs and nonreactive astrocytes allow determining the degree of similarity between NSCs and reactive astrocytes and the extent of injury-specific gene expression.
A small number of candidates shared by reactive astrocytes and endogenous NSCs have already been identified and tested, including glial fibrillary acidic protein (GFAP), Nestin, Musashi, DSD1-proteoglycan, and Tenascin-C (for review, see Götz et al., 2015; Robel et al., 2011; Sirko et al., 2009). However, these proteins also appear in injury conditions without reactive proliferation of astrocytes and/or neurosphere formation (Kamphuis et al., 2012; Robel at al., 2011), thus emphasizing the need for additional molecular insights. Toward this aim, we compared genomewide expression of astrocytes reacting to stab wound with astrocytes from the intact adult GM, as well as an existing expression profile of endogenous NSCs located in the adult SEZ (Beckervordersandforth et al., 2010).

More at link.

Friday, June 21, 2013

VEGFR1 and VEGFR2 Involvement in Extracellular Galectin-1- and Galectin-3-Induced Angiogenesis

We need angiogenesis to supply blood to any migrating stem cells or migratory neurogenesis. Ask your doctor to translate and put into a useful stroke protocol. Unless you ask, nothing is going to get done.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0067029

Abstract

Aim

Accumulating evidence suggests that extracellular galectin-1 and galectin-3 promote angiogenesis. Increased expression of galectin-1 and/or galectin-3 has been reported to be associated with tumour progression. Thus, it is critical to identify their influence on angiogenesis.

Methods

We examined the individual and combined effects of galectin-1 and galectin-3 on endothelial cell (EC) growth and tube formation using two EC lines, EA.hy926 and HUVEC. The activation of vascular endothelial growth factor receptors (VEGFR1 and VEGFR2) was determined by ELISA and Western blots. We evaluated the VEGFR1 and VEGFR2 levels in endosomes by proximity ligation assay.

Results

We observed different responses to exogenous galectins depending on the EC line. An enhanced effect on EA.hy926 cell growth and tube formation was observed when both galectins were added together. Focusing on this enhanced effect, we observed that together galectins induced the phosphorylation of both VEGFR1 and VEGFR2, whereas galectin-1 and −3 alone induced VEGFR2 phosphorylation only. In the same way, the addition of a blocking VEGFR1 antibody completely abolished the increase in tube formation induced by the combined addition of both galectins. In contrast, the addition of a blocking VEGFR2 antibody only partially inhibited this effect. Finally, the addition of both galectins induced a decrease in the VEGFR1 and VEGFR2 endocytic pools, with a significantly enhanced effect on the VEGFR1 endocytic pool. These results suggest that the combined action of galectin-1 and galectin-3 has an enhanced effect on angiogenesis via VEGFR1 activation, which could be related to a decrease in receptor endocytosis.

Friday, August 31, 2012

Protein May Play Part in Future Heart Failure

Talk to your researcher/doctor and have them explain the difference between Galectin-1, useful for stem cells and Galectin-3.
http://www.medpagetoday.com/Cardiology/CHF/34513
Galectin-3 (Gal-3), a marker of cardiac fibrosis, is associated with an increased risk of heart failure and death, researchers found.
Over a mean follow-up of nearly 9 years, those with elevated levels of Gal-3 had a significant 28% (95% CI 1.14 to 1.43, P
. "This collective experimental evidence suggests that Gal-3 may play a causal in cardiac remodeling," the authors stated.
However, adding Gal-3 to clinical factors resulted in only minor improvements in net reclassification. It also did not substantially increase the C-statistic (0.855 to 0.859).
Nonetheless, this is the first time that it's been shown that Gal-3 has a relationship with future heart failure, noted David Morrow, MD, MPH, and Michelle O'Donoghue, MD, MPH, of Brigham and Women's Hospital in Boston, in an accompanying editorial.
Although Gal-3 has been associated with adverse events in those with heart failure, it has not been evaluated as a predictor of incident heart failure in apparently healthy people.
Cardiac fibrosis, of which Gal-3 is a marker, plays an important role in the development of heart failure. Earlier identification of elevated levels of this betagalactoside-binding lectin might offer the opportunity to treat people long before heart failure develops, researchers said.
To fill in the gap, Levy and colleagues evaluated 3,353 participants enrolled in the offspring cohort of the community-based Framingham Heart Study.
The mean age of participants was 59 and 53% of them were women. Overall, Gal-3 levels were higher in women than men (median 14.3 ng/mL versus 13.1 ng/mL, P<0 .05=".05" p="p"> Also, those with higher concentrations of the protein tended to be older and have more cardiovascular risk factors such as high blood pressure, diabetes, previous coronary artery disease, a higher body mass index, and a lower estimated glomerular filtration rate (eGFR; P less than 0.0001, for the trend for all).
When researchers performed a multivariate analysis, only eGFR was dropped from the list of risk factors above, while B-type natriuretic peptide (BNP) was added.
Examining the echocardiographic data, researchers found Gal-3 was significantly associated with positive left ventricular remodeling. Having higher levels of the protein conferred twice the odds of having elevated left ventricular mass, they wrote.
But Gal-3 was not associated with fractional shortening, left ventricular systolic dysfunction, or left atrial size.
Crude heart failure rates progressed in a step-wise fashion with increasing Gal-3 quartiles.
During a mean follow-up period of 8.1 years, 5.1% of patients experienced first heart failure events.
The upper limits for Gal-3 quartiles for men and women were 15.4 ng/ml to 47.7 ng/ml and 16.8 ng/ml to 52.1 ng/ml, respectively. The lower limits were 3.9 ng/ml to 11.1 ng/ml for men and 5.0 ng/ml to 12.0 ng/ml for women.
Among the 25% of people with the highest Gal-3 levels, the annual rate of heart failure was 12 per 1,000 person-years compared with 3 per 1,000 person-years for the 25% of participants with the lowest levels.
Researchers added BNP to the multivariate analysis and found that high Gal-3 levels increased the risk of a first heart failure incident by a significant 23%. However, BNP was associated with a significant 46% increased risk.
There was no difference regarding Gal-3 levels between those with preserved ejection fraction and depressed ejection fraction.
Levy and colleagues suggested that directly modulating that Gal-3 pathway may be beneficial in these patients. They called for more study into how assessment of Gal-3 can help this patient population.
Morrow and O'Donoghue noted that Gal-3 is also sensitive to fibrotic conditions in other areas such as the liver, lungs, and kidneys. For that reason, it may difficult to include the protein in a screening strategy.
Study limitations included the modest number of heart failure events and the possibility that Gal-3 levels are influenced by other conditions. Also, the results may not be generalizable because patients were mostly Caucasian.



Rest at the link.

Monday, April 9, 2012

Neural stem cells, adult neurogenesis and Galectin-1: From bench to bedside

More useful neurogenesis and stem cells.
http://onlinelibrary.wiley.com/doi/10.1002/dneu.22023/abstract

Abstract

Neural stem cells (NSCs) in the adult brain have been a consistent focus of biomedical research largely because of their potential clinical application. To fully exploit this potential, the molecular mechanisms that regulate NSCs must be clarified. Several lines of evidence show that a multi-functional protein, Galectin-1, is expressed and has a functional role in a subset of adult NSCs. Researchers, including our group, have explored the physiological role of Galectin-1 in NSCs and its application in the treatment of animal models of neurological disorders such as brain ischemia and spinal cord injury. Here, we summarize what is currently known regarding the role of Galectin-1 in adult NSCs. Furthermore, we discuss current issues in researching the role of Galectin-1 in adult NSCs under both physiological and pathological conditions.